These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 31309675)
1. The aspartimide problem persists: Fluorenylmethyloxycarbonyl-solid-phase peptide synthesis (Fmoc-SPPS) chain termination due to formation of N-terminal piperazine-2,5-diones. Samson D; Rentsch D; Minuth M; Meier T; Loidl G J Pept Sci; 2019 Jul; 25(7):e3193. PubMed ID: 31309675 [TBL] [Abstract][Full Text] [Related]
2. The aspartimide problem in Fmoc-based SPPS. Part I. Mergler M; Dick F; Sax B; Weiler P; Vorherr T J Pept Sci; 2003 Jan; 9(1):36-46. PubMed ID: 12587881 [TBL] [Abstract][Full Text] [Related]
3. Problem of aspartimide formation in Fmoc-based solid-phase peptide synthesis using Dmab group to protect side chain of aspartic acid. Ruczyński J; Lewandowska B; Mucha P; Rekowski P J Pept Sci; 2008 Mar; 14(3):335-41. PubMed ID: 17975850 [TBL] [Abstract][Full Text] [Related]
5. The aspartimide problem in Fmoc-based SPPS. Part III. Mergler M; Dick F J Pept Sci; 2005 Oct; 11(10):650-7. PubMed ID: 15849777 [TBL] [Abstract][Full Text] [Related]
6. Preventing aspartimide formation in Fmoc SPPS of Asp-Gly containing peptides--practical aspects of new trialkylcarbinol based protecting groups. Behrendt R; Huber S; White P J Pept Sci; 2016 Feb; 22(2):92-7. PubMed ID: 26751703 [TBL] [Abstract][Full Text] [Related]
8. New t-butyl based aspartate protecting groups preventing aspartimide formation in Fmoc SPPS. Behrendt R; Huber S; Martí R; White P J Pept Sci; 2015 Aug; 21(8):680-7. PubMed ID: 26077723 [TBL] [Abstract][Full Text] [Related]
9. The aspartimide problem in Fmoc-based SPPS. Part II. Mergler M; Dick F; Sax B; Stähelin C; Vorherr T J Pept Sci; 2003 Aug; 9(8):518-26. PubMed ID: 12952393 [TBL] [Abstract][Full Text] [Related]